Showing results (231-240 of 324) with videos related to

Sort By:
Pageof 33
The Journal of Antibiotics|October 1, 1989
UK-69,753, a novel member of the efrotomycin family of antibiotics. I. Taxonomy of the producing organism, fermentation and isolationM S Pacey, M R Jefson, L H Huang, et al.
British Journal of Cancer|May 20, 2004
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerA O'Donnell, I Judson, M Dowsett, et al.
International Journal of Cancer|October 1, 1994
Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin-sensitive (A2780) and -resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysisI M Huxham, A L Barlow, A D Lewis, et al.
British Journal of Cancer|December 1, 1996
In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022H L McLeod, V G Brunton, N Eckardt, et al.
British Journal of Cancer|January 1, 1997
Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9S M Bailey, M D Wyatt, F Friedlos, et al.
Anti-Cancer Drug Design|April 1, 1996
The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554E O Aboagye, A D Lewis, M A Graham, et al.
Oncogene|December 3, 2013
Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteinsJ R Smith, E de Billy, S Hobbs, et al.
British Journal of Cancer|February 12, 1998
The relationship between tumour oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR-4554E O Aboagye, R J Maxwell, M R Horsman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1994
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials GroupG Catimel, J B Vermorken, M Clavel, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 1, 1990
How many tests are required in the diagnosis of palpable breast abnormalities?J R Hardy, T J Powles, I Judson, et al.
Pageof 33